Tocagen Inc (NASDAQ:TOCA) shares saw unusually-strong trading volume on Wednesday . Approximately 910,106 shares were traded during trading, an increase of 248% from the previous session’s volume of 261,641 shares.The stock last traded at $5.94 and had previously closed at $5.12.
Several equities analysts have commented on TOCA shares. Zacks Investment Research downgraded shares of Tocagen from a “buy” rating to a “hold” rating in a research report on Tuesday. Chardan Capital reissued a “buy” rating on shares of Tocagen in a research report on Tuesday, April 23rd. ValuEngine downgraded shares of Tocagen from a “buy” rating to a “hold” rating in a research report on Monday, May 13th. Leerink Swann started coverage on shares of Tocagen in a research report on Monday, April 15th. They set a “market perform” rating and a $10.26 target price on the stock. Finally, Cantor Fitzgerald started coverage on shares of Tocagen in a research report on Thursday, April 25th. They set an “overweight” rating and a $28.00 target price on the stock. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $16.30.
The company has a current ratio of 5.05, a quick ratio of 5.05 and a debt-to-equity ratio of 0.75. The firm has a market cap of $141.27 million, a PE ratio of -2.43 and a beta of 3.78.
In other news, Director Faheem Hasnain purchased 43,000 shares of the firm’s stock in a transaction on Thursday, May 30th. The stock was bought at an average cost of $4.66 per share, for a total transaction of $200,380.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have acquired 53,000 shares of company stock valued at $244,880 over the last 90 days. Corporate insiders own 10.90% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Arbitrage SA lifted its stake in shares of Tocagen by 72,350.0% in the first quarter. BNP Paribas Arbitrage SA now owns 4,347 shares of the company’s stock valued at $47,000 after buying an additional 4,341 shares during the period. Creative Planning bought a new stake in shares of Tocagen in the first quarter valued at about $117,000. Stratos Wealth Partners LTD. lifted its stake in shares of Tocagen by 9.0% in the fourth quarter. Stratos Wealth Partners LTD. now owns 11,449 shares of the company’s stock valued at $94,000 after buying an additional 949 shares during the period. Dowling & Yahnke LLC bought a new stake in shares of Tocagen in the first quarter valued at about $132,000. Finally, American International Group Inc. lifted its stake in shares of Tocagen by 11.7% in the first quarter. American International Group Inc. now owns 13,103 shares of the company’s stock valued at $142,000 after buying an additional 1,368 shares during the period. Institutional investors own 35.09% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Tocagen (NASDAQ:TOCA) Sees Strong Trading Volume” was first published by Ticker Report and is owned by of Ticker Report. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/4369593/tocagen-nasdaqtoca-sees-strong-trading-volume.html.
Tocagen Company Profile (NASDAQ:TOCA)
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Featured Story: What is a portfolio manager?
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.